<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00960557</url>
  </required_header>
  <id_info>
    <org_study_id>OXC101-100</org_study_id>
    <nct_id>NCT00960557</nct_id>
  </id_info>
  <brief_title>Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden</brief_title>
  <acronym>OXi4503</acronym>
  <official_title>A Multicenter, Open-label Phase 1b/2 Study to Assess the Safety and Clinical Activity of Intravenous Combretastatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Primary or Secondary Hepatic Tumor Burden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mateon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mateon Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects
      with relapsed or refractory carcinomas with hepatic tumor burden.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine progression-free survival (PFS).</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Combretastatin A1 Diphosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combretastatin A1 Diphosphate (OXi4503)</intervention_name>
    <description>OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.</description>
    <arm_group_label>Combretastatin A1 Diphosphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed carcinoma. Tumor must be relapsed or
             refractory to standard therapies, or have no acceptable standard therapy.

          2. Measurable disease by RECIST criteria.

          3. Subjects must be at least 28 days from other investigational therapy and at least 2
             weeks after chemotherapy or radiation therapy.

          4. Age 18 years or older.

          5. Eastern Cooperative Oncology Group (ECOG) Performance Score of less than 1.

          6. Life expectancy of greater than 12 weeks.

          7. Hemoglobin greater than 10 g/dL.

          8. Adequate hepatic function.

          9. Adequate renal function.

         10. Adequate bone marrow reserve.

         11. Able to maintain potassium, calcium and magnesium levels within normal ranges.

         12. Must be able to provide written informed consent.

         13. All women of childbearing potential (WOCBP) must have a negative serum pregnancy test.

         14. WOCBP and fertile men and their partners must agree to use an effective form of
             contraception during the study and for 90 days after the last dose of study
             medication.

        Exclusion Criteria:

          1. Uncontrolled CNS metastases.

          2. No other active malignancies.

          3. Poorly controlled hypertension.

          4. Recent history of serious cardiovascular conditions.

          5. Recent history of CVA, TIA, or intermittent claudication.

          6. Current anticoagulation therapy.

          7. History of cardiac arrhythmias.

          8. Abnormal ECG findings.

          9. Subjects who require concomitant medications which cause QTc prolongation.

         10. Major surgery within 30 days of treatment, or minor surgery within 7 days of
             treatment.

         11. Uncontrolled, clinically significant active infection.

         12. Subjects who are pregnant or lactating.

         13. Subjects with any other intercurrent medical condition.

         14. Subjects with a history of solid organ transplant or bone marrow transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Adelaide Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jason Lickliter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Mainwaring, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mater Adult Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Millward, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Charles Gairdner Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OXiGENE Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OXiGENE Investigational Site</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OXiGENE Investigational Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OXiGENE Investigational Site</name>
      <address>
        <city>Bentleigh</city>
        <state>Victoria</state>
        <zip>3165</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.oxigene.com/index.php</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2009</study_first_submitted>
  <study_first_submitted_qc>August 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2009</study_first_posted>
  <last_update_submitted>August 22, 2011</last_update_submitted>
  <last_update_submitted_qc>August 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatic tumor burden</keyword>
  <keyword>liver cancer</keyword>
  <keyword>liver carcinoma</keyword>
  <keyword>carcinoma</keyword>
  <keyword>hepatic cancer</keyword>
  <keyword>hepatic carcinoma</keyword>
  <keyword>VDA</keyword>
  <keyword>Vascular Disrupting Agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Combretastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

